Joint Clinical Trials Office
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25 (OFSET)
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 10, 2024
A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment For Relapsed/Refractory Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 29, 2024
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC)
Study Status:
Open to Enrollment
Primary Investigator:
Date: November 1, 2024
A Phase 1, Multicenter, Open-Label Study of CB-012, a CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Study Status:
Open to Enrollment
Primary Investigator:
Date: November 26, 2024
A Phase 1b/2 Study of BGB-11417 as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Study Status:
Open to Enrollment
Primary Investigator:
Date: November 26, 2024
Real-world evaluation of the HistoSonics Edison® System for treatment of liver tumors across multidisciplinary users
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 12, 2024
A randomized, double-blind, placebo-controlled study of LMN-201 for prevention of C. difficile infection recurrence (RePreve).
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 13, 2024
A Phase 3, Randomized, Double-Blind, Placebo-Controlled study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 13, 2024
Comprehensive Assessment of Cancer Theranostics Response; Investigating the Intent to Change Treatment Decisions Based on TRAQinform Theranostics
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 13, 2024
Habit Awareness Device for Treatment of Onychophagia
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 13, 2024